Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
272 studies found for:    "Diffuse scleroderma"
Show Display Options
Rank Status Study
21 Recruiting Scleroderma Registry
Conditions: Systemic Sclerosis;   Scleroderma
Intervention:
22 Recruiting Duke Scleroderma Clinic Patient Registry
Conditions: Scleroderma;   Systemic Sclerosis
Intervention: Other: Registry
23 Active, not recruiting Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Subjects With Systemic Sclerosis With Interstitial Lung Disease
Conditions: Scleroderma, Systemic;   Sclerosis, Systemic;   Systemic Scleroderma;   Systemic Sclerosis
Interventions: Drug: Pomalidomide (CC-4047);   Drug: Placebo
24 Recruiting Scleroderma Registry & Repository at the Hospital for Special Surgery
Condition: Scleroderma
Intervention:
25 Active, not recruiting Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
Conditions: Scleroderma;   Systemic Sclerosis;   Raynaud Phenomena;   Raynaud's Disease
Interventions: Device: Celution Device;   Other: Placebo
26 Recruiting Zibotentan Better Renal Scleroderma Outcome Study
Conditions: Scleroderma;   Scleroderma Renal Crisis;   Chronic Kidney Disease
Intervention: Drug: Zibotentan
27 Completed
Has Results
A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Conditions: Scleroderma, Diffuse;   Scleroderma, Systemic
Intervention: Drug: Abatacept
28 Completed
Has Results
High Dose Cyclophosphamide for Treatment of Scleroderma
Condition: Scleroderma
Intervention: Drug: IV Cyclophosphamide
29 Recruiting Endothelial Microparticles in Systemic Sclerosis Pulmonary Hypertension
Conditions: Systemic Sclerosis;   Pulmonary Hypertension;   Scleroderma
Intervention: Other: No intervention given
30 Completed Effectiveness and Safety of Lidocaine for Scleroderma
Condition: Scleroderma
Interventions: Drug: Lidocaine 2% without vessel constrictor;   Other: Placebo - physiological solution 0,9%
31 Recruiting Safety & Suitability of Dabigatran to Inhibit Thrombin in Scleroderma
Conditions: Scleroderma;   Interstitial Lung Disease
Intervention: Drug: dabigatran etexilate
32 Active, not recruiting Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Ambrisentan
33 Withdrawn Scleroderma Treatment With Celution Processed ADRCs Registry
Condition: Scleroderma
Intervention:
34 Not yet recruiting Effects of Probiotics on Gastrointestinal Symptoms and on the Immune System in Patients With Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Interventions: Other: Probiotic;   Other: Placebo
35 Not yet recruiting Study to Compare the Efficacy of Mycophenolate Mofetil in Systemic Sclerosis Related Early Interstitial Lung Disease
Conditions: Systemic Sclerosis;   Scleroderma;   Interstitial Lung Disease
Interventions: Drug: Mycophenolate mofetil;   Drug: Placebo
36 Active, not recruiting Rituximab in Systemic Sclerosis
Condition: Systemic Sclerosis
Interventions: Drug: Rituximab;   Drug: Placebo (NaCl)
37 Completed Scleroderma Lung: Role of Gastroesophageal Reflux, Microaspiration and Cough
Condition: Scleroderma Lung
Intervention:
38 Terminated
Has Results
Placebo Controlled Trial of Bosentan in Scleroderma Patients
Conditions: Systemic Scleroderma;   Pulmonary Hypertension
Interventions: Drug: Bosentan;   Drug: Placebo
39 Completed Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis
Conditions: Systemic Sclerosis;   Scleroderma
Intervention: Drug: Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody
40 Unknown  A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
Conditions: Pulmonary Arterial Hypertension;   Systemic Sclerosis;   Scleroderma Spectrum of Diseases;   Connective Tissue Disease;   Pulmonary Hypertension
Interventions: Drug: Tadalafil monotherapy;   Drug: Ambrisentan monotherapy;   Drug: tadalafil and ambrisentan

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years